Angiopoietin-based interventions for treating cerebral malaria

Patent metadata

Field	Value
Publication number	US-9968653-B2
Application number	US-201715414925-A
Country	US
Kind code	B2
Filing date	Jan 25, 2017
Priority date	Nov 1, 2013
Publication date	May 15, 2018
Grant date	May 15, 2018

Abstract

The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.

First claim

What is claimed is:

1. A method of preventing or ameliorating severe cerebral malaria in a subject infected with Plasmodium falciparum , the method comprising: (a) selecting a subject with more than 0.1% parasitemia; and (b) administering a pharmaceutical composition comprising a therapeutically effective amount of a fusion protein comprising at least one fibrinogen-like domain of angiopoietin-1 fused to an immunoglobulin Fc fragment to the subject in need thereof.

2. The method of claim 1 , wherein the administration of the fusion protein prevents or ameliorates at least one indication selected from the group consisting of neurological impairment and vascular leakage.

3. The method of claim 2 , wherein the at least one indication of neurological impairment is selected from the group consisting of impaired balance or coordination, motor impairment, loss of reflexes and self-preservation, long term neurocognitive injury and impairment, memory deficits, affective disorders, lack of hygiene-related behavior, convulsion, and fitting.

4. The method of claim 1 , wherein the administration of the fusion protein prevents or reduces loss of blood brain barrier integrity.

5. The method of claim 1 , wherein the fusion protein is administered at a dose of 15 mg/kg of the subject's body weight.

6. The method of claim 1 , wherein the fusion protein is administered subcutaneously.

7. The method of claim 1 , wherein the fusion protein is administered in combination with a therapeutic agent.

8. The method of claim 7 , wherein the therapeutic agent is artesunate.

9. The method of claim 1 , wherein the fusion protein comprises a first fibrinogen-like domain of angiopoietin-1 fused at its C-terminal end to the N-terminal end of an Fc fragment and the Fc fragment fused at its C-terminal end to the N-terminal end of a second fibrinogen-like domain of angiopoietin-1.

10. The method of claim 1 , wherein the fusion protein is AngF1-Fc-F1.

11. The method of claim 1 , wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 2.

12. The method of claim 1 , wherein the Fc fragment is an IgG Fc domain.

13. The method of claim 12 , wherein the Fc fragment is a human IgG1 Fc domain.

14. The method of claim 1 , wherein the method comprises ameliorating severe cerebral malaria via administration of the pharmaceutical composition.

15. The method of claim 11 , wherein the fusion protein consists of the amino acid sequence of SEQ ID NO:2.

16. The method of claim 1 , wherein the fusion protein is a dimer comprising a first AngF1-Fc-F1 and a second AngF1-Fc-F1, wherein the first and second AngF1-Fc-F1s associate through intramolecular association of the Fc fragments.

Assignees

• Regeneron Pharma
• Univ Health Network

Inventors

• Purcell Ngambo Lisa Arleen
• Higgins Sarah J
• Kain Kevin C

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P33/06

  Antimalarials · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title